Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Tax Provisions (2022 - 2025)

Amylyx Pharmaceuticals (AMLX) has 4 years of Tax Provisions data on record, last reported at $46000.0 in Q4 2025.

  • For Q4 2025, Tax Provisions rose 105.36% year-over-year to $46000.0; the TTM value through Dec 2025 reached $46000.0, up 107.46%, while the annual FY2025 figure was $46000.0, 107.46% up from the prior year.
  • Tax Provisions reached $46000.0 in Q4 2025 per AMLX's latest filing, up from -$859000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $2.0 million in Q4 2023 and bottomed at -$859000.0 in Q4 2024.
  • Average Tax Provisions over 4 years is $494090.9, with a median of $174000.0 recorded in 2022.
  • The widest YoY moves for Tax Provisions: up 1300.0% in 2023, down 216.44% in 2023.
  • A 4-year view of Tax Provisions shows it stood at $579000.0 in 2022, then soared by 240.07% to $2.0 million in 2023, then plummeted by 143.63% to -$859000.0 in 2024, then soared by 105.36% to $46000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Tax Provisions were $46000.0 in Q4 2025, -$859000.0 in Q4 2024, and $242000.0 in Q1 2024.